Principles of In Vitro Diagnostic (IVD) Medical Devices Classification

Working group update

Tatyana Buryakina, PhD

IVD Working Group Chair

Roszdravnadzor

Russia

New Work Item Proposal

review and update the GHTF / SG1 / N045: 2008 document on
Principles of In Vitro Diagnostic (IVD) Medical Devices Classification

Initiator
Russian Federation

- NWIP approved in March 2019 MC meeting in Moscow
- Working group formed and started working in June 2019

FIRST WORKING GROUP
PRIMARILY FOCUSED ON

IVD MEDICAL DEVICES

Working Group members

Australia: TGA
Michelle McNiven

Brazil: ANVISA
Fabio Pereira Quintino

Canada: Health Canada
Monica Magidin

China: NIFDC
Ying Huang
Le Cui

European Union: Paul-Ehrlich Institute
Sigrid Nick

Japan: MHLW
Fumihito Takanashi
Manabu Fukuzawa

Japan: PMDA
Hiromi Yamada
Eri Orihara
Mika Togashi
Yasuyuki Sakurai

Russia: Roszdravnadzor
Tatyana Buryakina
Vladimir Antonov
Roman Bystrov

Singapore: HSA
Rama Sethuraman
Danny Ong

South Korea: MFDS
Yong-kyoung Lee
Young-wook Ahn

USA: FDA
Dina Jerebitski

WHO:
Irena Prat
Helena Ardura

AHWP:
Wen-Wei Tsai
Yung-Chuan Lee
Razan Asally
Mariammah Krishnasamy

PAHO:
Mariela Aranda
Noaris Marquez
Marcia Rodriguez

New Work Item Proposal

- **Objective**

Review and update of GHTF/SG1/ N045:2008 Principles of In Vitro Diagnostic (IVD) Medical Devices Classification based on modern state of development

- Rationale

new concepts and approaches have been emerged in laboratory diagnostics that are not reflected in the GHTF document (for example, genetic testing, companion diagnostics, SaMD, etc.)

- Goal

Increase in the harmonization and effectiveness of regulatory decision

Relevant existing documents

- 1. GHTF/SG1/N045:2008 Principles of In Vitro Diagnostic (IVD) Medical Devices Classification.
- 2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017.
- 3. Decision of the EEU Commission, dated 12.22.2015 № 173 “Rules for the classification of medical devices, depending on the potential risk of use”.
- 4. Medical Devices Regulations (SOR/98-282) (Canada).
- 5. Classification of IVD medical devices, December 2015, TGA (Australia).
- 6. Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices, June 2018, HSA (Singapore).
- 7. Resolution RDC № 36/2015, Article 4, IVD Classification Rules, ANVISA (Brazil).
- 8. AHWP/WG2/F001:2016 Principles of In Vitro Diagnostic (IVD) Medical Devices Classification” for format consistency with item 1.
- 9. Risk based classification of diagnostics for WHO Prequalification, May 2014, WHO

Working progress

NWIP APPROVAL
March 2019

First WG Tconf
June 2019

First face-to-face meeting in Moscow
Aug 2019

First Working Draft
Sept 2019

Second WG TConf
(*to be confirmed*)



Risk-based Classification

created by the Global Harmonization Task Force (GHTF)

Classification general approach

IV classes

A, B, C, D

Criteria: individual and public health risk level

		PUBLIC		
		Low	Moderate	High
INDIVIDUAL	Low	A	B	None
	Moderate	B	B	C
	High	C	C	D

7 rules

Criteria: intended use, specific characteristics

Risk-based classification was primarily created

❑ To:
determine the level of pre-market regulatory assessment that is required for an IVD medical device

❑ For:
regulatory control to be sufficient for each risk class to safeguard the health and safety of patients, users and other persons

❑ Outcome:
grouping IVDs into one of four classes representing increasing individual and public health risk

GHTF / SG1 / N045: 2008 Principles of In Vitro Diagnostic (IVD) Medical Devices Classification

Changes in Working Draft

- General approach maintained
- Rules modified considering modern technologies
- Added Definitions
- Updated references
- Added examples
- Structured

Main discussed points:

- Accessories` definition;
- SaMD classification;
- differentiation of “research use only” medical devices;
- Possible class changes while implementation

Current status

- Clear version of first WD is under WG consideration
- First comments received from Japan, EU, Canada and China

The “Process”

General plan and time schedule

Submission of a draft document to the MC to approve its placement for public consultation

March 2020

Adoption of the final version

September 2020


СПАСИБО
DANKSCHEEN
BİYAN
SHUKRIA
TINGKI
YAQHANYELAY
TASHAKKUR ATU
THANK
GRACIAS
SUKSAMA
EKHMET
ARIGATO
SHUKURIA
GOZAIMASHITA
EFCHARISTO
YOU
GRAZIE
MEHRBANI
PALDIES
KOMAPSUMNIDA
JUSPAXAR
BOLZÏN
MERCI
MINMONCHAR